93 related articles for article (PubMed ID: 15280844)
1. A phase II multicenter clinical trial of systemic bexarotene in psoriasis.
Smit JV; Franssen ME; de Jong EM; Lambert J; Roseeuw DI; De Weert J; Yocum RC; Stevens VJ; van De Kerkhof PC
J Am Acad Dermatol; 2004 Aug; 51(2):249-56. PubMed ID: 15280844
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
Duvic M; Martin AG; Kim Y; Olsen E; Wood GS; Crowley CA; Yocum RC;
Arch Dermatol; 2001 May; 137(5):581-93. PubMed ID: 11346336
[TBL] [Abstract][Full Text] [Related]
3. Systemic treatment of psoriatic patients with bexarotene decreases epidermal proliferation and parameters for inflammation, and improves differentiation in lesional skin.
Smit JV; de Jong EM; van Hooijdonk CA; Otero ME; Boezeman JB; van de Kerkhof PC
J Am Acad Dermatol; 2004 Aug; 51(2):257-64. PubMed ID: 15280845
[TBL] [Abstract][Full Text] [Related]
4. Phase II clinical trial of bexarotene gel 1% in psoriasis.
Breneman D; Sheth P; Berger V; Naini V; Stevens V
J Drugs Dermatol; 2007 May; 6(5):501-6. PubMed ID: 17679184
[TBL] [Abstract][Full Text] [Related]
5. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
van de Kerkhof PC; Segaert S; Lahfa M; Luger TA; Karolyi Z; Kaszuba A; Leigheb G; Camacho FM; Forsea D; Zang C; Boussuge MP; Paolozzi L; Wajdula J
Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis.
Gottlieb AB; Kang S; Linden KG; Lebwohl M; Menter A; Abdulghani AA; Goldfarb M; Chieffo N; Totoritis MC
Clin Immunol; 2004 Apr; 111(1):28-37. PubMed ID: 15093549
[TBL] [Abstract][Full Text] [Related]
7. Novel treatment of chronic severe hand dermatitis with bexarotene gel.
Hanifin JM; Stevens V; Sheth P; Breneman D
Br J Dermatol; 2004 Mar; 150(3):545-53. PubMed ID: 15030340
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies.
Govindan R; Crowley J; Schwartzberg L; Kennedy P; Williams C; Ekstrand B; Sandler A; Jaunakais D; Bolejack V; Ghalie R
J Clin Oncol; 2006 Oct; 24(30):4848-54. PubMed ID: 17050870
[TBL] [Abstract][Full Text] [Related]
9. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.
Gottlieb AB; Evans R; Li S; Dooley LT; Guzzo CA; Baker D; Bala M; Marano CW; Menter A
J Am Acad Dermatol; 2004 Oct; 51(4):534-42. PubMed ID: 15389187
[TBL] [Abstract][Full Text] [Related]
10. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.
Blumenschein GR; Khuri FR; von Pawel J; Gatzemeier U; Miller WH; Jotte RM; Le Treut J; Sun SL; Zhang JK; Dziewanowska ZE; Negro-Vilar A
J Clin Oncol; 2008 Apr; 26(11):1879-85. PubMed ID: 18398153
[TBL] [Abstract][Full Text] [Related]
11. Etanercept: efficacy and safety.
Jiménez-Puya R; Gómez-García F; Amorrich-Campos V; Moreno-Giménez JC
J Eur Acad Dermatol Venereol; 2009 Apr; 23(4):402-5. PubMed ID: 19210697
[TBL] [Abstract][Full Text] [Related]
12. Bexarotene as add-on to antipsychotic treatment in schizophrenia patients: a pilot open-label trial.
Lerner V; Miodownik C; Gibel A; Kovalyonok E; Shleifer T; Goodman AB; Ritsner MS
Clin Neuropharmacol; 2008; 31(1):25-33. PubMed ID: 18303488
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
Kannangara AP; Levitan D; Fleischer AB
J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
[TBL] [Abstract][Full Text] [Related]
14. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
[TBL] [Abstract][Full Text] [Related]
15. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.
Moore A; Gordon KB; Kang S; Gottlieb A; Freundlich B; Xia HA; Stevens SR
J Am Acad Dermatol; 2007 Apr; 56(4):598-603. PubMed ID: 17113190
[TBL] [Abstract][Full Text] [Related]
16. Effects of oral bexarotene (targretin) on the minimal erythema dose for broadspectrum UVB light.
Smit JV; De Jong EM; Van De Kerkhof PC
Skin Pharmacol Appl Skin Physiol; 2003; 16(4):237-41. PubMed ID: 12784063
[TBL] [Abstract][Full Text] [Related]
17. Leflunomide in the treatment of psoriasis: results of a phase II open trial.
Tlacuilo-Parra JA; Guevara-Gutiérrez E; Rodríguez-Castellanos MA; Ornelas-Aguirre JM; Barba-Gómez JF; Salazar-Páramo M
Br J Dermatol; 2004 May; 150(5):970-6. PubMed ID: 15149511
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
Tyring S; Gordon KB; Poulin Y; Langley RG; Gottlieb AB; Dunn M; Jahreis A
Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937
[TBL] [Abstract][Full Text] [Related]
19. Bexarotene: new preparation. Cutaneous lymphoma: too many adverse effects.
Prescrire Int; 2004 Jun; 13(71):94-7. PubMed ID: 15233146
[TBL] [Abstract][Full Text] [Related]
20. Tacalcitol in the treatment of psoriasis vulgaris: the Spanish experience.
Lecha M; Mirada A; López S; Artés M;
J Eur Acad Dermatol Venereol; 2005 Jul; 19(4):414-7. PubMed ID: 15987284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
